Mesothelioma

P=N/A, N=60, Recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

Additionally, 17 biomarkers of nanofiber-induced toxicity were identified as potential targets for predictive, animal-free screening. These early markers may be of value for assessing nanofiber toxicity.

P=N/A, N=30, Active, not recruiting, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Nov 2026

FDCS is a rare neoplasm with variable morphologic and staining patterns. To the best of our knowledge, this is the first reported instance of pleura-based FDCS with epithelioid morphology and aberrant expression of cytokeratins. Diagnosis of such cases can be challenging, which has to be separated from the morphologic mimicries, particularly carcinoma and mesothelioma.

P1, N=260, Recruiting, IDEAYA Biosciences | Not yet recruiting --> Recruiting

P2, N=41, Active, not recruiting, Istituto Oncologico Veneto IRCCS | Recruiting --> Active, not recruiting

P1, N=19, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Recruiting --> Active, not recruiting | N=365 --> 19

To understand this, we generated human embryonic stem cells that stably express doxycycline inducible BAP1 shRNAs...Thus, our results demonstrate that the knockdown of histone H2A deubiquitinase BAP1 restricts the lineage specification ability of human embryonic stem cells to a large extent, while it does not affect their undifferentiated state. Our results have implication in the study of early human development as well as cancer biology.

Thus, the tailored therapeutic approach that is described here for lung cancer may extend to patients with mesothelioma, rather than the previous "one therapy fits all" approach. Progress in the rare thymic epithelial tumors has been less marked; however, recent insights into the biology of thymic tumors have resulted in the development of clinically relevant interventions.

P=N/A, N=347, Recruiting, Beijing Tsinghua Chang Gung Hospital

Single biomarkers like miRNAs, mesothelin, and VOCs show promise, but further validation is needed in larger cohorts with correct control groups. A multi-omics approach, which integrates biomarker panels from various -omics areas, has the potential to enhance diagnostic accuracy.

While preclinical research has identified multiple potential vulnerabilities in BAP1-deficient tumors-including sensitivity to EZH2-, HDAC-, PARP-, and FGFR-inhibitors-translating these findings to the clinic remains a challenge. In this review, we provide a comprehensive overview of BAP1's molecular functions in mesothelioma, with a focus on their translation into clinical therapeutics for this hard-to-treat malignancy.